Increlex has been acquired by Eton on December 19, 2024

This site is intended for US healthcare professionals only

Go to Patient Site

Increlex has been acquired by Eton on December 19, 2024

This site is intended for US healthcare professionals only

Go to Patient Site
Join Patient Support Network

Because Each Child is Unique:

Ask your doctor if INCRELEX® is the appropriate treatment for your child.

INCRELEX® is used to treat children who are very short for their age because their bodies do not make enough insulin-like growth factor-1 (IGF-1). This condition is called Severe Primary IGF-1 Deficiency or SPIGFD. INCRELEX® should not be used instead of growth hormone and has not been studied for use in children under 2 years of age.

Learn more

OLIVE'S JOURNEY

Olive has been diagnosed with Severe Primary IGF-1 Deficiency and shares her journey as a patient.

If your child is not growing at a rate that they should be and their growth hormone levels are normal, very low levels of IGF-1 may be the cause. Talk to your doctor about having your child screened for Severe Primary IGF-1 Deficiency. Ask your doctor for more information to find out if INCRELEX® is an appropriate treatment option for your child.

Learn more

What is Severe Primary IGF-1 Deficiency?

Learn about the importance of IGF-1 for growth and how Severe-Primary IGF-1 Deficiency, or SPIGFD, is diagnosed.

About INCRELEX®

Learn how INCRELEX® works and is used to treat Severe Primary IGF-1 deficiency including important safety information about side effects that may occur during treatment.

Staying on Treatment

Discover how you can help your child continue treatment with INCRELEX® as prescribed by their doctor.

Eton Cares is Here to Help You

Sign up to learn more about our full-service patient program designed to help you and your child along the treatment journey.

INDICATION

INCRELEX® (mecasermin) is indicated for the treatment of growth failure in pediatric patients aged 2 years and older with severe primary IGF-1 deficiency* (IGFD), or with hormone (GH) gene deletion who have developed neutralizing antibodies to GH.

Limitations of use: INCRELEX is not a substitute to GH for approved GH indications. INCRELEX is not indicated for use in patients with secondary forms of IGFD, such as GH deficiency, malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.

*Severe primary IGF-1 deficiency (IGFD) is defined by height standard deviation score ≤ -3.0 and basal IGF-1 standard deviation score ≤ -3.0 and normal or elevated GH.

IMPORTANT SAFETY INFORMATION

Contraindications

  • Hypersensitivity: to mecasermin (rhIGF-1), any of the inactive ingredients in INCRELEX, or who have experienced a severe hypersensitivity to INCRELEX. Allergic reactions have been reported, including anaphylaxis requiring hospitalization.

Intravenous Administration

Closed Epiphyses

Malignant Neoplasia in pediatric patients with malignant neoplasia or a history of malignancy.

Warnings and Precautions

  • Hypoglycemia: INCRELEX should be administered 20 minutes before or after a meal or snack and should not be administered when the meal or snack is omitted. Glucose monitoring and INCRELEX dose titration are recommended until a well-tolerated dose is established and as medically indicated.
  • Intracranial Hypertension: Funduscopic examination is recommended at the initiation of and periodically during the course of therapy.
  • Lymphoid Tissue Hypertrophy: Patients should have periodic examinations to rule out potential complications.
  • Slipped Capital Femoral Epiphysis: Carefully evaluate any pediatric patient with the onset of a limp or hip/knee pain during INCRELEX therapy.
  • Progression of Scoliosis: Patients with a history of scoliosis, treated with INCRELEX, should be monitored.
  • Malignant Neoplasia: There have been postmarketing reports of malignant neoplasia in pediatric patients who received treatment with INCRELEX. The tumors were observed more frequently in patients who received INCRELEX at higher than recommended doses or at doses that produced serum IGF-1 levels above the normal reference ranges for age and sex. Monitor all patients receiving INCRELEX carefully for development of neoplasms. If malignant neoplasia develops, discontinue INCRELEX treatment.
  • Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preserved Solution: Serious and fatal adverse reactions including “gasping syndrome” can occur in neonates and infants treated with benzyl alcohol-preserved drugs. Use of INCRELEX in infants is not recommended.

Adverse Reactions

Common adverse reactions include hypoglycemia, local and systemic hypersensitivity, and tonsillar hypertrophy.

To report a suspected adverse event related to INCRELEX, contact Eton Pharmaceuticals, Inc. at 1-855-224-0233 or the U.S. Food and Drug Administration (FDA) at www.fda.gov/safety/Medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information for more information.

© 2024 Eton Pharmaceuticals, Inc. All rights reserved. 1769-v1